After multiple high-profile clinical trial terminations for selective estrogen receptor degraders (SERDs) in breast cancer, Olema Oncology is taking a stab at the notoriously hard-to-treat disease with a new dual-mechanism approach.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,